Drug profile · INN
foscarbidopa
VYALEV
foscarbidopa (VYALEV) is a dopa decarboxylase inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — foscarbidopa
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
foscarbidopa (VYALEV) is a dopa decarboxylase inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
DOPA decarboxylase inhibitor
Primary target: Aromatic-L-amino-acid decarboxylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is foscarbidopa?
foscarbidopa (VYALEV) is a dopa decarboxylase inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for foscarbidopa?
VYALEV is a marketed brand name for foscarbidopa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of foscarbidopa?
foscarbidopa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.